Vertex Pharmaceuticals
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| rareDisease | ×1.16 | 4 |
| metabolic | ×0.91 | 3 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| discovery | ×1.50 | 5 |
| preclinical | ×0.76 | 5 |
Strategy profile
Based on 15 disclosed transactions, Vertex Pharmaceuticals concentrates its licensing activity in RareDisease, Metabolic, and Other. Vertex Pharmaceuticals pays a 1.32x premium over market median, with the strongest premiums in RareDisease (1.16x). Their most common deal structure is Collaboration, with an average disclosed value of $1.0B. Most recent activity: 2025.
Premium by therapeutic area
How Vertex Pharmaceuticals pays relative to peer medians in each TA
Pipeline coverage & gaps
Vertex Pharmaceuticals has disclosed activity in 2 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| CollaborationPrimary | 7 | $207M | $625M |
| Option | 3 | $48M | $2.9B |
| License | 3 | $58M | $403M |
| Acquisition | 1 | $55M | $60M |
| Co Development | 1 | $900M | $1.1B |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2025 | oRNA (circular RNA) platform-based LNP-delivered gene-editing programs for SCD and TDT | ReNAgade Therapeutics / Orna Therapeutics | Sickle Cell Disease | discovery | $65M | $700M |
| 2025 | Circular RNA (oRNA) platform programs for SCD and β-thalassemia, plus up to 10 additional products | Orna Therapeutics | sickle cell disease and beta-thalassemia | discovery | $65M | $4.3B |
| 2024 | C-Stem cell-manufacturing technology (stem cell platform for islet-cell therapies) | TreeFrog Therapeutics | Type 1 Diabetes | preclinical | $25M | $780M |
| 2023 | Circular-RNA gene-editing programs for SCD and TDT | Orna Therapeutics | sickle cell disease and transfusion-dependent β-thalassemia | preclinical | $65M | $4.0B |
| 2023 | Cas9 gene-editing technology for ex vivo hemoglobinopathy medicines (BCL11A) | Editas Medicine | sickle cell disease and β-thalassemia | preclinical | $50M | $100M |
| 2023 | CRISPR/Cas9 hypoimmune gene-edited cell therapy for T1D | CRISPR Therapeutics | Type 1 Diabetes | preclinical | $100M | $330M |
| 2023 | ImmunoGen ADC technology platform (targeted conditioning agents for gene editing) | ImmunoGen, Inc. | sickle cell disease, transfusion-dependent beta thalassemia | discovery | $15M | $352M |
| 2022 | ENTR-701 (DM1 EEV platform programs) | Entrada Therapeutics | myotonic dystrophy type 1 (DM1) | preclinical | $250M | $735M |
| 2022 | base editing platform (in vivo gene editing programs) | Verve Therapeutics | undisclosed serious liver disease | discovery | $60M | $466M |
| 2022 | — | Verve Therapeutics, Inc. | undisclosed liver disease | discovery | $25M | $466M |
| 2022 | complement portfolio | Catalyst Biosciences, Inc. | dry AMD | preclinical | $55M | $60M |
| 2021 | CTX001 | CRISPR Therapeutics | sickle cell disease, transfusion-dependent beta thalassemia | phase_3 | $900M | $1.1B |
| 2021 | CTX001 | CRISPR Therapeutics AG | sickle cell disease and transfusion-dependent beta thalassemia | phase_3 | $900M | $1.1B |
| 2020 | Moderna mRNA/LNP delivery technology for CRISPR-based CF gene-editing therapies | Moderna, Inc. | cystic fibrosis | preclinical | $75M | $455M |
| 2020 | Gene-editing therapies for cystic fibrosis | Moderna | cystic fibrosis | discovery | $75M | $455M |
How this is computed
For each Vertex Pharmaceuticals deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 10 disclosed deal premiums vs. peer medians. Raw premium 1.322, clamped to [0.7, 1.5].